Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stock
Kabra Drugs Ltd, established in 1989, specializes in manufacturing ether derivatives along with other pharmaceutical and permaculture products.
The company has expanded its product line to include hand sanitizers and antimicrobial gels, becoming a sole manufacturer of some disinfectant products in India.
Kabra Drugs maintains state-of-the-art facilities approved by WHO-GMP, cGMP, and Schedule 'M', enabling business with government entities and NGOS.
Despite manufacturing capabilities, the company is facing operational challenges due to lack of working capital, prompting cost reduction efforts.
Kabra Drugs is a registered supplier to the Ministry of Defence and aims to expand its reach to global markets with new product developments.
Pharmaceuticals & Biotechnology
Pharmaceuticals
51 Cr
Moderate Risk
10.2
34.1
-0.0
1.7
35.52
12.21
Sales CAGR
Profit CAGR
ROE
ROCE
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Kabra Drugs Ltd (KABRADG) is currently trading at 23.19 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Kabra Drugs Ltd, established in 1989, specializes in manufacturing ether derivatives along with other pharmaceutical and permaculture products. The company has expanded its product line to include hand sanitizers and antimicrobial gels, becoming a sole manufacturer of some disinfectant products in India. Kabra Drugs maintains state-of-the-art facilities approved by WHO-GMP, cGMP, and Schedule 'M', enabling business with government entities and NGOS. Despite manufacturing capabilities, the company is facing operational challenges due to lack of working capital, prompting cost reduction efforts. Kabra Drugs is a registered supplier to the Ministry of Defence and aims to expand its reach to global markets with new product developments.
Over the past 52 weeks, Kabra Drugs Ltd has traded between a low of ₹12.21 and a high of ₹35.52. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Kabra Drugs Ltd has a market capitalization of approximately 50.81. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Kabra Drugs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 10.22 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 50.81 Cr, Kabra Drugs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Kabra Drugs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Kabra Drugs Ltd is 10.22. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Bearish
5
Neutral
6
Bullish
3
Bearish
25
Neutral
6
Bullish
15
Bearish
20
Neutral
0
Bullish
12
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
23.19 | 51 Cr | 10.22 | 1.72 | 0.00 | 16.75 | 19.05 | 5.76 | ||
29.20 | 51 Cr | 5.61 | 0.70 | 0.00 | 11.78 | 15.93 | 10.72 | ||
6.28 | 50 Cr | -1.44 | 0.00 | 0.00 | 50.81 | -2.49 | -3.78 | ||
24.71 | 50 Cr | 92.56 | 2.18 | 0.00 | 2.96 | 6.55 | 1.22 | ||
157.50 | 49 Cr | 12.93 | 1.26 | 1.29 | 11.58 | 14.72 | 7.89 | ||
28.46 | 44 Cr | -1.00 | 0.46 | 0.00 | -43.08 | -15.40 | -14.10 | ||
| Median: 6 Co. | — | 26.59 | 50 Cr | 7.92 | 0.98 | 0.00 | 11.68 | 10.63 | 3.49 |
Postal Ballot Result
Kabra Drugs' postal ballot approved two special resolutions — change of company name and addition to the MOA object clause — with 34 of 35 members (2,746,027 votes; 99.85%) in favour and 1 member (4,000 votes; 0.15%) against.
Postal Ballot Result
Kabra Drugs Ltd postal ballot (remote e‑voting closed 10 Jun 2026) approved two special resolutions — change of company name and addition to MOA object clause — with 2,746,027 (99.85%) votes in favor of 2,750,027 total valid votes.
Postal Ballot Result
Shareholders approved two special resolutions — change of company name and addition to the Memorandum of Association — via postal ballot (deemed passed 10 Jun 2026) with 2,746,027 votes (99.85%) in favour.
Postal Ballot Result
Kabra Drugs Ltd shareholders approved two special resolutions — change of company name and addition to the Memorandum of Association objects — via remote postal ballot (deemed passed 10 Jun 2026); votes: 2,746,027 (99.85%) for, 4,000 (0.15%) against, total 2,750,027.
